PDCD1LG2 and lymphoma: These results demonstrate that the use of current checkpoint blockade therapy may be best reserved for lymphoma subtypes with genomic alterations that promote high levels of PD-L1/PD-L2 expression (i.e., cHL, PMBCL, PCNSL, and PTL).